N. Hanna

N. Hanna, C. Gridelli, J. Heymach, 2008, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Randomized Trial of Amifostine in Locally Advanced Non-Small-Cell Lung Cancer Patients Receiving Chemotherapy and Hyperfractionated Radiation: Radiation Therapy Oncology Group Trial 98-01

N. Hanna, N. H. Hanna, 2006 .

Ethnic and Racial Differences in the Smoking-Related Risk of Lung Cancer

N. Hanna, 2007 .

Therapy for Stage IV Non-Small-Cell Lung Cancer Without Driver Alterations: ASCO and OH (CCO) Joint Guideline Update Summary.

N. Hanna, S. Temin, G. Masters, 2020, JCO oncology practice.

Coping Skills Practice and Symptom Change: A Secondary Analysis of a Pilot Telephone Symptom Management Intervention for Lung Cancer Patients and Their Family Caregivers.

N. Hanna, V. Champion, L. Einhorn, 2018, Journal of pain and symptom management.

A Phase II Study with Cetuximab and Radiation Therapy for Patients with Surgically Resectable Esophageal and GE Junction Carcinomas: Hoosier Oncology Group G05-92

N. Hanna, H. Choy, R. Timmerman, 2013, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Statistical controversies in clinical research: futility analyses in oncology–lessons on potential pitfalls from a randomized controlled trial

N. Hanna, R. Kaiser, E. Lesaffre, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

Is"chemobrain" a transient state? A prospective pilot study among persons with non-small cell lung cancer.

N. Hanna, J. Hook, P. Lysaker, 2008, The journal of supportive oncology.

Current Standards and Clinical Trials in Systemic Therapy for Stage III Lung Cancer: What Is New?

N. Hanna, 2015, American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting.

Support service use and interest in support services among lung cancer patients.

N. Hanna, V. Champion, L. Einhorn, 2013, Lung cancer.

Distressed family caregivers of lung cancer patients: an examination of psychosocial and practical challenges

N. Hanna, J. Ostroff, C. Mosher, 2013, Supportive Care in Cancer.

Nintedanib for the treatment of non-small-cell lung cancer

N. Hanna, S. Rashdan, 2014, Expert opinion on pharmacotherapy.

Pemetrexed in Second Line and beyond Small Cell Lung Cancer: A Hoosier Oncology Group Phase II Study

N. Hanna, R. Govindan, Menggang Yu, 2009, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Screening studies for fatigue and laboratory correlates in cancer patients undergoing treatment.

N. Hanna, G. Sledge, L. Einhorn, 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

Randomized phase III trial comparing irinotecan/cisplatin with etoposide/cisplatin in patients with previously untreated extensive-stage disease small-cell lung cancer.

N. Hanna, P. Bunn, P. Ellis, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Paclitaxel–Carboplatin Alone or with Bevacizumab for Non–Small-Cell Lung Cancer

N. Hanna, 2008 .

Preoperative chemotherapy in patients with resectable non-small cell lung cancer: results of the MRC LU22/NVALT 2/EORTC 08012 multicentre randomised trial and update of systematic review

N. Hanna, 2008 .

Testicular cancer--discoveries and updates.

N. Hanna, L. Einhorn, 2014, The New England journal of medicine.

Lung Cancer Screening Knowledge Among Internal Medicine Residents in a University Program

N. Hanna, S. Urrutia Argueta, Samuel Urrutia Argueta, 2020, Journal of Cancer Education.

Development and Usability Testing of a Computer-Tailored Decision Support Tool for Lung Cancer Screening: Study Protocol

N. Hanna, S. Rawl, L. Carter-Harris, 2017, JMIR research protocols.

Erlotinib in-Previously Treated Non-Small-Cell Lung CancerShepherd FA (for the National Cancer Institute of Canada Clinical Trials Group Univ of Toronto; et al N Engl J Med 353:123-132, 2005§

N. Hanna, 2006 .

Testicular cancer: The usage of central review for pathology diagnosis of orchiectomy specimens.

D. Grignon, N. Hanna, Liang Cheng, 2017, Urologic oncology.

Phase II study of BBR 3464 as treatment in patients with sensitive or refractory small cell lung cancer

M. Socinski, N. Hanna, T. Hensing, 2006, Anti-cancer drugs.

Phase II Multicenter Study of the Antiepidermal Growth Factor Receptor Monoclonal Antibody Cetuximab in Combination With Platinum-Based Chemotherapy in Patients With Platinum-Refractory Metastatic and/or Recurrent Squamous Cell Carcinoma of the Head and Neck

N. Hanna, 2006 .

Long-term survival in a patient with stage IV non-small-cell lung carcinoma after bone metastasectomy.

N. Hanna, A. Agarwala, 2005, Clinical lung cancer.

Erlotinib and bevacizumab in newly diagnosed performance status 2 or elderly patients with nonsquamous non-small-cell lung cancer, a phase II study of the Hoosier Oncology Group: LUN04-77.

N. Hanna, Menggang Yu, S. Jalal, 2013, Clinical lung cancer.

ANtiangiogenic Second-line Lung cancer Meta-Analysis on individual patient data in non-small cell lung cancer: ANSELMA.

H. Groen, G. Scagliotti, N. Hanna, 2022, European journal of cancer.

A phase II study assessing the safety and efficacy of ASP1650 in male patients with relapsed refractory germ cell tumors

N. Hanna, D. Feldman, L. Einhorn, 2022, Investigational New Drugs.

Women's Susceptibility to Tobacco Carcinogens and Survival After Diagnosis of Lung CancerHenschke CI, for the International Early Lung Cancer Action Program Investigators (Cornell Univ, New York; et al) JAMA 296:180–184, 2006§

N. Hanna, 2007 .

MEK114653: A randomized, multicenter, phase II study to assess efficacy and safety of trametinib (T) compared with docetaxel (D) in KRAS-mutant advanced non-small cell lung cancer (NSCLC).

P. Jänne, N. Hanna, E. Smit, 2013 .

Phase II Clinical Trial of Chemotherapy-Naïve Patients≥70 Years of Age Treated With Erlotinib for Advanced Non–Small-Cell Lung Cancer

N. Hanna, 2008 .

Randomized, phase III trial comparing irinotecan/cisplatin (IP) with etoposide/cisplatin (EP) in patients (pts) with previously untreated, extensive-stage (ES) small cell lung cancer (SCLC)

N. Hanna, P. Bunn, P. Ellis, 2005 .

Never smokers and lung cancer risk: A case-control study of epidemiological factors

N. Hanna, 2007 .

Combined chemoradiotherapy in small cell lung cancer.

N. Hanna, N. Hahn, 2005, Hematology/oncology clinics of North America.

Nintedanib plus pemetrexed versus placebo plus pemetrexed in patients with relapsed or refractory, advanced non-small cell lung cancer (LUME-Lung 2): A randomized, double-blind, phase III trial.

N. Hanna, R. Kaiser, M. Ahn, 2016, Lung cancer.

Survival update for the phase III study of pemetrexed vs docetaxel in non-small cell lung cancer (NSCLC).

N. Hanna, H. Lim, F. Demarinis, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase III trial of cisplatin (P) plus etoposide (E) plus concurrent chest radiation (XRT) with or without consolidation docetaxel (D) in patients (pts) with inoperable stage III non-small cell lung cancer (NSCLC): HOG LUN 01–24/USO-023

C. Yiannoutsos, N. Hanna, R. Govindan, 2007 .

A phase II study of weekly gemcitabine and paclitaxel in patients with previously untreated stage IIIb and IV non-small cell lung cancer.

N. Hanna, L. Einhorn, A. Sandler, 2002, Lung cancer.

Gefitinib-Sensitizing EGFR Mutations in Lung Cancer Activate Anti-Apoptotic Pathways

N. Hanna, 2006 .

Computed Tomography Screening and Lung Cancer Outcomes

C. Begg, S. Swensen, J. Jett, 2008 .

Addressing tobacco use in patients with cancer: a survey of American Society of Clinical Oncology members.

K. Cummings, N. Hanna, R. Herbst, 2013, Journal of oncology practice.

Randomized Phase III Trial Comparing Irinotecan/Cisplatin With Etoposide/Cisplatin in Patients With Previously Untreated Extensive-Stage Disease Small-Cell Lung Cancer

N. Hanna, 2007 .

B5-01: Phase III trial of cisplatin (P) plus etoposide (E) plus concurrent chest radiation (XRT) with or without consolidation docetaxel (D) in patients (pts) with inoperable stage III non-small cell lung cancer (NSCLC): HOG LUN 01-24/USO-023

Cynthia S. Johnson, C. Yiannoutsos, N. Hanna, 2007 .

Locally Advanced Non-Small Cell Lung Cancer: Optimal Chemotherapeutic Agents and Duration

N. Hanna, S. Jalal, H. Mamdani, 2015, Current Treatment Options in Oncology.

Paclitaxel Plus Bevacizumab in Patients with Chemosensitive Relapsed Small Cell Lung Cancer: A Safety, Feasibility, and Efficacy Study from the Hoosier Oncology Group

N. Hanna, R. Govindan, Menggang Yu, 2010, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Survival of Patients with Stage I Lung Cancer Detected on CT Screening

N. Hanna, 2008 .

Neoadjuvant and Adjuvant Immunotherapy in Early-Stage Non-Small Cell Lung Cancer

N. Hanna, N. Shukla, 2021, Lung Cancer.

Association of Immune-Related Adverse Events and Efficacy Outcomes With Consolidation Pembrolizumab After Chemoradiation in Patients With Inoperable Stage III Non-Small-Cell Lung Cancer.

N. Hanna, S. Althouse, G. Durm, 2021, Clinical lung cancer.

Increased HER2 Gene Copy Number Is Associated With Response to Gefitinib Therapy in Epidermal Growth Factor Receptor-Positive Non-Small-Cell Lung Cancer PatientsCappuzzo F, Varella-Garcia M, Shigematsu H, et al (Univ of Colorado, Aurora; Bellaria Hosp, Italy; CINECA-Interuniversity Consortium, Bolog

N. Hanna, 2006 .

Case for Stopping Targeted Therapy When Lung Cancer Progresses on Treatment in Hospice-Eligible Patients.

Thomas J. Smith, G. Giaccone, N. Hanna, 2017, Journal of oncology practice.

Clinical and Biological Features Associated With Epidermal Growth Factor Receptor Gene Mutations in Lung Cancers

N. Hanna, 2006 .

Second-line treatment of non-small cell lung cancer: big targets, small progress; small targets, big progress?

N. Hanna, 2006, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Prospective Phase II Study of Gefitinib for Chemotherapy-Naïve Patients With Advanced Non–Small-Cell Lung Cancer With Epidermal Growth Factor Receptor Gene Mutations

N. Hanna, 2007 .

Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy.

Miklos Pless, N. Hanna, C. Desch, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Pemetrexed plus Cetuximab in Patients with Recurrent Non-small Cell Lung Cancer (NSCLC): A Phase I/II Study from the Hoosier Oncology Group

N. Hanna, M. Edelman, Menggang Yu, 2009, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Elderly patients benefit from second-line cytotoxic chemotherapy: a subset analysis of a randomized phase III trial of pemetrexed compared with docetaxel in patients with previously treated advanced non-small-cell lung cancer.

N. Hanna, K. Kelly, P. Bunn, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Advances in the treatment of second-line non-small-cell lung cancer.

N. Hanna, 2005, Lung cancer.

Large cell carcinoma of the lung mimicking a germ cell tumor: the potential value of chromosome analysis.

N. Hanna, T. Ulbright, G. Vance, 2005, Lung cancer.

Prospective Study of Gefitinib in Epidermal Growth Factor Receptor Fluorescence In Situ Hybridization–Positive/Phospho-Akt–Positive or Never Smoker Patients With Advanced Non–Small-Cell Lung Cancer: The ONCOBELL Trial

N. Hanna, 2008 .

Somatic Mutations of the HER2 Kinase Domain in Lung Adenocarcinomas

N. Hanna, 2006 .

A phase II trial of cetuximab as therapy for recurrent non-small cell lung cancer (NSCLC).

N. Hanna, R. Govindan, T. Lynch, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Vinorelbine Plus Cisplatin vs Observation in Resected Non–Small-Cell Lung Cancer

N. Hanna, N. H. Hanna, 2006 .

Phase I Study of Amrubicin and Cyclophosphamide in Patients With Advanced Solid Organ Malignancies: HOG LUN 07-130

N. Hanna, S. Badve, L. Einhorn, 2017, American journal of clinical oncology.

Role of Adjuvant Chemotherapy in Patients With Resected Non-Small-Cell Lung Cancer: Reappraisal With a Meta-analysis of Randomized Controlled TrialsHotta K, Matsuo K, Ueoka H, et al (Okayama Univ Med School, Japan) J Clin Oncol 22:3860-3867, 2004§

N. Hanna, 2006 .

A phase 1 study of combined guadecitabine and cisplatin in platinum refractory germ cell cancer

B. Christensen, N. Hanna, K. Nephew, 2020, Cancer medicine.

Can radiotherapy potentiate the effectiveness of immune checkpoint inhibitors in lung cancer?

N. Hanna, L. Einhorn, F. Kong, 2017, Future oncology.

A randomized discontinuation phase II study of sorafenib versus placebo in patients with non-small cell lung cancer who have failed at least two prior chemotherapy regimens: E2501

N. Hanna, D. Carbone, J. Schiller, 2008 .

The Impact of Smoking Status on the Behavior and Survival Outcome of Patients With Advanced Non-small Cell Lung Cancer: A Retrospective AnalysisToh C-K, Wong E-H, Lim W-T, et al (Natl Cancer Ctr, Singapore Chest 126:1750-1756, 2004§

N. Hanna, 2006 .

Varenicline, an α4β2 Nicotinic Acetylcholine Receptor Partial Agonist, vs Sustained-Release Bupropion and Placebo for Smoking Cessation: A Randomized Controlled Trial

N. Hanna, 2007 .

PL-5 A phase III study of pemetrexed vs. docetaxel in patients with advanced non-small-cell lung cancer (NSCLC) who were previously treated with chemotherapy

N. Hanna, P. Bunn, F. Shepherd, 2003 .

Acceptance and Commitment Therapy for Symptom Interference inAdvanced Lung Cancer and Caregiver Distress: A Pilot RandomizedTrial

N. Hanna, L. Einhorn, S. Jalal, 2019 .

Phase I/IIa Study of Cetuximab With Gemcitabine Plus Carboplatin in Patients With Chemotherapy-Naïve Advanced Non–Small-Cell Lung Cancer

N. Hanna, 2007 .

Phase I Trial of Carboplatin and Paclitaxel With Escalating Doses of Oral Topotecan in Patients With Solid Tumors

N. Hanna, C. Sweeney, K. Fife, 2003, American journal of clinical oncology.

Phase I Trial of Topotecan Plus Vinorelbine With/Without Filgrastim (G-CSF) in Patients With Refractory Malignancies

N. Hanna, K. Fife, A. Sandler, 2002, American journal of clinical oncology.

Induction Chemotherapy Followed by Chemoradiotherapy Compared With Chemoradiotherapy Alone for Regionally Advanced Unresectable Stage III Non–Small-Cell Lung Cancer: Cancer and Leukemia Group B

N. Hanna, 2008 .

Phase II Study of Consolidation Paclitaxel After Concurrent Chemoradiation in Poor-Risk Stage III Non–Small-Cell Lung Cancer: SWOG S9712

N. Hanna, 2008 .

Simultaneous Chemoradiotherapy Compared With Radiotherapy Alone After Induction Chemotherapy in Inoperable Stage IIIA or IIIB Non–Small-Cell Lung Cancer: Study CTRT99/97 by the Bronchial Carcinoma Therapy Group

N. Hanna, 2008 .

Randomized Phase III Intergroup Trial of Etoposide and Cisplatin With or Without Paclitaxel and Granulocyte Colony-Stimulating Factor in Patients With Extensive-Stage Small-Cell Lung Cancer: Cancer and Leukemia Group B Trial 9732

N. Hanna, 2006 .

A phase 2 trial of consolidation pembrolizumab following concurrent chemoradiation for patients with unresectable stage III non–small cell lung cancer: Hoosier Cancer Research Network LUN 14‐179

N. Hanna, S. Jalal, R. Zon, 2020, Cancer.

Lysosomal acid lipase, CSF1R, and PD-L1 determine functions of CD11c+ myeloid-derived suppressor cells

N. Hanna, H. Du, J. Wan, 2022, JCI insight.

Efficacy of Varenicline, an α4β2 Nicotinic Acetylcholine Receptor Partial Agonist, vs Placebo or Sustained-Release Bupropion for Smoking Cessation: A Randomized Controlled TrialJorenby DE, for the Varenicline Phase 3 Study Group (Univ of Wisconsin, Madison; et al) JAMA 296:56–63, 2006§

N. Hanna, 2007 .

Therapy for Stage IV Non-Small-Cell Lung Cancer With Driver Alterations: ASCO and OH (CCO) Joint Guideline Update.

N. Hanna, Gregory Riely, L. Gaspar, 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Respiratory Symptoms, Pulmonary Function, and Markers of Inflammation Among Bar Workers Before and After a Legislative Ban on Smoking in Public Places

N. Hanna, N. H. Hanna, 2008 .

Lume-lung 2: A multicenter, randomized, double-blind, phase III study of nintedanib plus pemetrexed versus placebo plus pemetrexed in patients with advanced nonsquamous non-small cell lung cancer (NSCLC) after failure of first-line chemotherapy.

N. Hanna, R. Kaiser, M. Ahn, 2013 .

A phase II study assessing the safety and efficacy of ASP1650 in male patients with relapsed refractory germ cell tumors

N. Hanna, D. Feldman, L. Einhorn, 2022, Investigational New Drugs.

P3-091: A Phase I study of continuous oral treatment with the triple angiokinase inhibitor BIBF 1120 together with pemetrexed in previously treated patients with non-small cell lung cancer

N. Hanna, P. Ellis, D. Shapiro, 2007 .

Two drugs versus one drug in non-small-cell lung cancer: are we asking the right questions?

N. Hanna, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A Phase II Trial of Atezolizumab Plus Carboplatin Plus Pemetrexed Plus Bevacizumab in the Treatment of Patients with Stage IV Non-Squamous Non-Small Cell Lung Cancer: Big Ten Cancer Research Consortium (BTCRC)- LUN 17-139.

N. Hanna, R. Gentzler, S. Althouse, 2022, Clinical lung cancer.

Phase II Multicenter Study of the Epidermal Growth Factor Receptor Antibody Cetuximab and Cisplatin for Recurrent and Refractory Squamous Cell Carcinoma of the Head and Neck

N. Hanna, 2006 .

O-106 A phase II trial of cetuximab as therapy for recurrent non-small cell lung cancer (NSCLC)

P. Jänne, N. Hanna, R. Govindan, 2005 .

High-Dose Chemotherapy and Autologous Peripheral-Blood Stem-Cell Transplantation for Relapsed Metastatic Germ Cell Tumors: The Indiana University Experience.

N. Hanna, L. Einhorn, C. Albany, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Long‐Term Survival of Good‐Risk Germ Cell Tumor Patients After Postchemotherapy Retroperitoneal Lymph Node Dissection: A Comparison of BEP × 3 vs. EP × 4 and Treating Institution

N. Hanna, L. Einhorn, C. Albany, 2017, Clinical genitourinary cancer.

Practice Makes Perfect: The Rest of the Story in Testicular Cancer as a Model Curable Neoplasm.

W. Lowrance, N. Hanna, T. Powles, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Outcomes of patients with stage III non-small cell lung cancer (NSCLC) that harbor a STK11 mutation

N. Hanna, Josiah J. An, S. Mott, 2020, Translational lung cancer research.

Treatment of small cell lung cancer.

N. Hanna, A. Kurup, 2004, Critical reviews in oncology/hematology.

Etoposide, ifosfamide and cisplatin (VIP) plus concurrent radiation therapy for previously untreated limited small cell lung cancer (SCLC): a Hoosier Oncology Group (HOG) phase II study.

Sin-Ho Jung, N. Hanna, A. Sandler, 2002, Lung cancer.

Carboplatin plus paclitaxel and sequential radiation followed by consolidation carboplatin and paclitaxel in patients with previously untreated locally advanced NSCLC. A Hoosier Oncology Group (HOG) phase II study.

N. Hanna, L. Einhorn, A. Sandler, 2002, Lung cancer.

Dose-volume analysis of radiation pneumonitis in non-small-cell lung cancer patients treated with concurrent cisplatinum and etoposide with or without consolidation docetaxel.

N. Hanna, Menggang Yu, R. Mcgarry, 2010, International journal of radiation oncology, biology, physics.

Randomized Controlled Trial of Resection Versus Radiotherapy After Induction Chemotherapy in Stage IIIA-N2 Non–Small-Cell Lung Cancer

N. Hanna, 2008 .

Quality of Life in Head and Neck Cancer Patients After Treatment With High-Dose Radiotherapy Alone or in Combination With Cetuximab

N. Hanna, 2008 .

Radiotherapy plus Cetuximab for Squamous-Cell Carcinoma of the Head and NeckBonner JA, Harari PM, Giralt J, et al (Univ of Alabama, Birmingham; Univ of Wisconsin, Madison; Vall d'Hebron Univ, Barcelona; et al) N Engl J Med 354:567–578, 2006§

N. Hanna, 2007 .

E11-04: The role of irinotecan in the treatment of small cell lung cancer

N. Hanna, 2007 .

A phase II study assessing the safety and efficacy of ASP1650 in male patients with incurable platinum refractory germ cell tumors.

N. Hanna, D. Feldman, L. Einhorn, 2020 .

Reply to M.E.H.M. Van Hoef.

N. Hanna, S. Temin, T. Oliver, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Prognostic Value of Teratoma in Primary Tumor and Postchemotherapy Retroperitoneal Lymph Node Dissection Specimens in Patients With Metastatic Germ Cell Tumor.

N. Hanna, L. Einhorn, M. Chovanec, 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Long-term Survival of Good Risk Germ Cell Tumor Patients following Post-chemotherapy Retroperitoneal Lymph Node Dissection: A comparison of BEPx3 vs. EPx4 and treating institution

N. Hanna, L. Einhorn, C. Albany, 2017 .

Survival outcomes of patients with metastatic germ cell tumor (mGCT) treated from 1998 to 2012: The Indiana University (IU) experience.

N. Hanna, L. Einhorn, C. Albany, 2016 .

Phase III Study of Second-Line Chemotherapy for Advanced Non–Small-Cell Lung Cancer With Weekly Compared With 3-Weekly Docetaxel

N. Hanna, 2007 .

Systemic Therapy for Stage IV Non-Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update Summary.

N. Hanna, S. Temin, G. Masters, 2017, Journal of oncology practice.

MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling

N. Hanna, N. H. Hanna, 2008 .

Open-Label, Uncontrolled, Multicenter Phase II Study to Evaluate the Efficacy and Toxicity of Cetuximab As a Single Agent in Patients With Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck Who Failed to Respond to Platinum-Based Therapy

N. Hanna, 2008 .

Practical challenges in patients with stage III NSCLC receiving checkpoint inhibitors after chemoradiation

N. Hanna, N. Shukla, 2020, Lung cancer management.

Management of stage I testicular germ cell tumours

N. Hanna, L. Einhorn, M. Chovanec, 2016, Nature Reviews Urology.

Primary choriocarcinoma of the bladder with the detection of isochromosome 12p.

N. Hanna, T. Ulbright, L. Einhorn, 2002, The Journal of urology.

Testicular cancer: a reflection on 50 years of discovery.

N. Hanna, L. Einhorn, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A Double-Blind Randomized Discontinuation Phase-II Study of Sorafenib (BAY 43–9006) in Previously Treated Non–Small-Cell Lung Cancer Patients: Eastern Cooperative Oncology Group Study E2501

N. Hanna, H. Wakelee, D. Carbone, 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Therapy for Stage IV Non-Small-Cell Lung Cancer Without Driver Alterations: ASCO and OH (CCO) Joint Guideline Update.

N. Hanna, Gregory Riely, L. Gaspar, 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

TMPRSS2-ERG Fusion in an Uncommon Presentation of Prostate Cancer.

N. Hanna, Liang Cheng, N. Adra, 2017, Clinical genitourinary cancer.

The differential efficacy of pemetrexed according to NSCLC histology: a review of two Phase III studies.

G. Scagliotti, N. Hanna, F. Shepherd, 2009, The oncologist.

Advances in systemic therapy for non-small cell lung cancer

N. Hanna, Meagan E Miller, 2021, BMJ.

Systemic Therapy for Stage IV Non-Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update.

Thomas J. Smith, Thomas J Smith, Gregory J Riely, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Second‐Line Treatment Options in Non–Small‐Cell Lung Cancer: Report From an International Experts Panel Meeting of the Italian Association of Thoracic Oncology

N. Hanna, C. Gridelli, E. Felip, 2017, Clinical lung cancer.

Differential Effects of Gefitinib and Cetuximab on Non–small-cell Lung Cancers Bearing Epidermal Growth Factor Receptor Mutations

P. Jänne, N. Hanna, D. Tenen, 2005 .

Differential effects of gefitinib and cetuximab on non-small-cell lung cancers bearing epidermal growth factor receptor mutations.

P. Jänne, N. Hanna, D. Tenen, 2005, Journal of the National Cancer Institute.

Phase III study of carboplatin and paclitaxel alone or with sorafenib in advanced non-small-cell lung cancer.

G. Scagliotti, N. Hanna, Michael Thomas, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Targeting FGFR in Squamous Cell Carcinoma of the Lung

N. Hanna, N. Hashemi-Sadraei, 2017, Targeted Oncology.

Phase III Study of Erlotinib in Combination With Cisplatin and Gemcitabine in Advanced Non–Small-Cell Lung Cancer: The Tarceva Lung Cancer Investigation Trial

N. Hanna, 2008 .

Phase I-IIa study of BMS-690514, an EGFR, HER-2 and -4 and VEGFR-1 to -3 oral tyrosine kinase inhibitor, in patients with advanced or metastatic solid tumours.

N. Hanna, J. Baselga, R. Herbst, 2013, European journal of cancer.

Cisplatin, fluorouracil, celecoxib, and RT in resectable esophageal cancer: preliminary results.

N. Fineberg, N. Hanna, R. Govindan, 2004, Oncology.

Sunitinib Plus Paclitaxel in Patients with Advanced Esophageal Cancer: A Phase II Study from the Hoosier Oncology Groupe

N. Hanna, Ziyue Liu, Y. Tong, 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Clinical benefit of a precision medicine based approach for guiding treatment of refractory cancers

Milan Radovich, Todd C. Skaar, Liang Cheng, 2016, Oncotarget.

In reply [8]

N. Hanna, 2006 .

Recombinant human angiostatin (rhAngiostatin) in combination with paclitaxel and carboplatin in patients with advanced non-small-cell lung cancer: a phase II study from Indiana University.

C. Yiannoutsos, N. Hanna, R. Hickey, 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

Brain metastases as the primary site of relapse in two randomized phase III pemetrexed trials in advanced non-small-cell lung cancer.

G. Scagliotti, N. Hanna, C. Langer, 2012, Clinical lung cancer.

Review: Advanced non-small cell lung cancer: the role of maintenance therapy

N. Hanna, A. Agarwala, 2010, Therapeutic Advances in Medical Oncology.

Gefitinib Plus Celecoxib in Chemotherapy-Naïve Patients with Stage IIIB/IV Non-small Cell Lung Cancer: A Phase II Study from the Hoosier Oncology Group

N. Hanna, Menggang Yu, L. Einhorn, 2008, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Salvage Therapy in Patients with Advanced Non-small Cell Lung Cancer

N. Hanna, P. Bedano, 2006, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

The value of platinum compounds in non-small-cell lung cancer.

N. Hanna, L. Einhorn, 2002, Clinical Lung Cancer.

The Story of Angiogenesis Inhibitors in Non-small-cell Lung Cancer: The Past, Present, and Future.

N. Hanna, M. Yan, N. Shukla, 2020, Clinical lung cancer.

Second-line chemotherapy for non-small-cell lung cancer: recent data with pemetrexed.

N. Hanna, 2004, Clinical lung cancer.

The impact of induction chemotherapy on the outcome of second-line therapy with pemetrexed or docetaxel in patients with advanced non-small-cell lung cancer.

N. Hanna, K. Kelly, P. Bunn, 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

Unlocking the biological clues of lung cancer.

N. Hanna, 2008, Journal of Thoracic Oncology.

Responsiveness to cetuximab without mutations in EGFR.

P. Jänne, N. Hanna, Z. Tsuchihashi, 2005, New England Journal of Medicine.

A phase II trial of cetuximab as therapy for recurrent non-small cell lung cancer (NSCLC): Final results

P. Jänne, N. Hanna, R. Govindan, 2005 .

Phase II trial of cetuximab in patients with previously treated non-small-cell lung cancer.

P. Jänne, N. Hanna, R. Govindan, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Economic and social changes among distressed family caregivers of lung cancer patients

C. Azzoli, N. Hanna, V. Champion, 2013, Supportive Care in Cancer.

Second-Line Chemotherapy and Beyond for Non-Small Cell Lung Cancer.

N. Hanna, G. Durm, 2017, Hematology/oncology clinics of North America.

Second-Line Chemotherapy and Beyond for Non-Small Cell Lung Cancer.

N. Hanna, G. Durm, 2017, Hematology/oncology clinics of North America.

A randomized, double‐blind, phase 2 trial of platinum therapy plus etoposide with or without concurrent vandetanib (ZD6474) in patients with previously untreated extensive‐stage small cell lung cancer: Hoosier Cancer Research Network LUN06‐113

N. Hanna, J. Patel, G. Masters, 2017, Cancer.

Targeting multiple angiogenic pathways simultaneously: experience with nintedanib in non-small-cell lung cancer.

N. Hanna, G. Durm, 2014, Future oncology.

Phase 2 Trial of Linifanib (ABT-869) in Patients with Advanced Non-small Cell Lung Cancer

N. Hanna, D. Gandara, R. Salgia, 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

A phase II trial of olanzapine, dexamethasone, and palonosetron for the prevention of chemotherapy-induced nausea and vomiting: a Hoosier oncology group study

Cynthia S. Johnson, N. Hanna, L. Einhorn, 2007, Supportive Care in Cancer.

Electronic Nicotine Delivery Systems: A Policy Statement from the American Association for Cancer Research and the American Society of Clinical Oncology

Jennifer A. Hobin, K. Viswanath, N. Hanna, 2015, Clinical Cancer Research.

Tobacco cessation and control a decade later: American society of clinical oncology policy statement update.

N. Hanna, J. Mulshine, Courtney A Tyne, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Adjuvant Epidermal Growth Factor Receptor Inhibitors in Non-Small Cell Lung Cancer.

N. Hanna, S. Jalal, Laura Lourdes, 2015, The oncologist.

Consolidation nivolumab plus ipilimumab or nivolumab alone following concurrent chemoradiation for patients with unresectable stage III non-small cell lung cancer: BTCRC LUN 16-081.

N. Hanna, S. Jalal, A. Ganti, 2022, Journal of Clinical Oncology.

Phase III study of cisplatin, etoposide, and concurrent chest radiation with or without consolidation docetaxel in patients with inoperable stage III non-small-cell lung cancer: the Hoosier Oncology Group and U.S. Oncology.

Cynthia S. Johnson, Constantin Yiannoutsos, Thomas Anderson, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Support service use and interest in support services among distressed family caregivers of lung cancer patients

B. Given, N. Hanna, V. Champion, 2013, Psycho-oncology.

Pemetrexed (Alimta®): improving outcomes in malignant pleural mesothelioma

N. Hanna, L. Budde, 2004, Expert review of anticancer therapy.

An update on current standards and clinical trials in systemic therapy for stage III NSCLC

N. Hanna, G. Durm, 2015 .

Multicenter phase I/II study of cetuximab with paclitaxel and carboplatin in untreated patients with stage IV non-small-cell lung cancer.

N. Hanna, K. Kelly, P. Bunn, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The shifting paradigm of biomarker-driven care in advanced non-small cell lung cancer (NSCLC).

N. Hanna, G. Durm, 2019, Translational lung cancer research.

Radiosurgery dose reduction for brain metastases on immunotherapy (RADREMI): A prospective phase I study protocol.

N. Hanna, S. McClelland, N. Agrawal, 2020, Reports of practical oncology and radiotherapy : journal of Greatpoland Cancer Center in Poznan and Polish Society of Radiation Oncology.

Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration Use for Subclassification and Genotyping of Lung Non-Small-Cell Carcinoma

N. Hanna, S. Jalal, K. Diab, 2018, Southern medical journal.

A phase II trial of chemotherapy plus pembrolizumab in patients with advanced NSCLC previously treated with a PD-1 or PD-L1 inhibitor: Big Ten Cancer Research Consortium BTCRC-LUN15-029.

N. Hanna, S. Perkins, S. Althouse, 2021 .

Phase II trial of brentuximab vedotin in relapsed/refractory germ cell tumors

N. Hanna, D. Feldman, S. Perkins, 2021, Investigational new drugs.

E-Cigarettes and Cancer Patients

K. Cummings, N. Hanna, N. Ikeda, 2014, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Cetuximab in non-small cell lung cancer

N. Hanna, F. Ademuyiwa, 2008, Expert opinion on biological therapy.

A phase II study of methylphenidate for the treatment of fatigue

N. Hanna, G. Sledge, L. Einhorn, 2006, Supportive Care in Cancer.

Development of a Symptom Management Intervention: Qualitative Feedback From Advanced Lung Cancer Patients and Their Family Caregivers

N. Hanna, V. Champion, S. Jalal, 2017, Cancer nursing.

Dimensional versus categorical use of the PHQ-9 depression scale among persons with non-small-cell lung cancer: a pilot study including quality-of-life comparisons.

N. Hanna, P. Lysaker, Kriscinda A. Whitney, 2010, The Journal of Supportive Oncology.

Barriers to mental health service use and preferences for addressing emotional concerns among lung cancer patients

N. Hanna, V. Champion, L. Einhorn, 2014, Psycho-oncology.

Phase III Trial of Gemcitabine Plus Carboplatin Versus Single-Agent Gemcitabine in the Treatment of Locally Advanced or Metastatic Non–Small-Cell Lung Cancer: The Swedish Lung Cancer Study Group

N. Hanna, 2007 .

Recent issues in first-line treatment of advanced non-small-cell lung cancer: Results of an International Expert Panel Meeting of the Italian Association of Thoracic Oncology.

N. Hanna, C. Gridelli, F. Shepherd, 2010, Lung cancer.

The role of maintenance chemotherapy in advanced nonsmall cell lung cancer

N. Hanna, S. Jalal, F. Ademuyiwa, 2009, Current opinion in oncology.

Prognostic factors in stage III non-small-cell lung cancer.

Cynthia S. Johnson, N. Hanna, F. Ademuyiwa, 2007, Clinical Lung Cancer.

Impact of smoke-free ordinance strength on smoking prevalence and lung cancer incidence

N. Hanna, S. Jalal, P. Loehrer, 2021, PLoS ONE.

Phase II study of fosaprepitant + 5HT3 receptor antagonist + dexamethasone in patients with germ cell tumors undergoing 5-day cisplatin-based chemotherapy: a Hoosier Cancer Research Network study

Cynthia S. Johnson, N. Hanna, L. Einhorn, 2016, Supportive Care in Cancer.

Addressing tobacco use and cessation in cancer patients: Practices, perceptions, and barriers reported by oncology providers.

K. Cummings, N. Hanna, R. Herbst, 2013 .

P76.62 RAMOSE: An Open-Label Randomized Phase II Study of Osimertinib with or without Ramucirumab in TKI-Naïve EGFR-Mutant Metastatic NSCLC

N. Hanna, G. Otterson, R. Hall, 2021 .

Helping patients quit tobacco: ASCO's efforts to help oncology care specialists.

N. Hanna, 2013, Journal of oncology practice.

Postoperative Radiotherapy for Stage II or III Non–Small-Cell Lung Cancer Using the Surveillance, Epidemiology, and End Results Database

N. Hanna, 2007 .

Postoperative chemotherapy for n2 non-small-cell lung cancer: conclusions are not black and white, but gray.

N. Hanna, L. Einhorn, 2006, Journal of Clinical Oncology.

Chemotherapy and Radiotherapy in the Treatment of Resectable Non–Small-Cell Lung Cancer

N. Hanna, E. Bernstein, S. Herbert, 2006, Annals of Surgical Oncology.

Understanding lung cancer screening behavior: Racial, gender, and geographic differences among Indiana long-term smokers

N. Hanna, P. Monahan, J. Slaven, 2018, Preventive medicine reports.

Lung cancer screening: what do long‐term smokers know and believe?

N. Hanna, S. Rawl, L. Carter-Harris, 2015, Health expectations : an international journal of public participation in health care and health policy.

Consolidation nivolumab/ipilimumab versus nivolumab following concurrent chemoradiation in patients with unresectable stage III NSCLC: A planned interim safety analysis from the BTCRC LUN 16-081 trial.

N. Hanna, S. Jabbour, J. Naidoo, 2020 .

Analysis of circulating tumor DNA in the phase 2 BTCRC LUN 16-081 trial of consolidation nivolumab with or without ipilimumab after chemoradiation in stage III non–small cell lung cancer.

A. Alizadeh, N. Hanna, C. Kunder, 2022, Journal of Clinical Oncology.

Cisplatin- Versus Carboplatin-Based Chemotherapy in First-Line Treatment of Advanced Non–Small-Cell Lung Cancer: An Individual Patient Data Meta-analysis

N. Hanna, 2008 .

Palliative chemotherapy beyond three courses conveys no survival or consistent quality-of-life benefits in advanced non-small-cell lung cancer

N. Hanna, 2008 .

Measurement of patients’ acceptable symptom levels and priorities for symptom improvement in advanced lung cancer

N. Hanna, L. Einhorn, S. Jalal, 2021, Supportive Care in Cancer.

Phase I Open-Label Study of Continuous Treatment with BIBF 1120, a Triple Angiokinase Inhibitor, and Pemetrexed in Pretreated Non–Small Cell Lung Cancer Patients

N. Hanna, R. Kaiser, P. Ellis, 2010, Clinical Cancer Research.

Carboplatin/nab-Paclitaxel and Pembrolizumab for Patients with Advanced Non-Small Cell Lung Cancer (NSCLC): Phase 1 Results.

N. Hanna, S. Jalal, R. Gentzler, 2017, International Journal of Radiation Oncology, Biology, Physics.

Randomized Pilot Trial of a Telephone Symptom Management Intervention for Symptomatic Lung Cancer Patients and Their Family Caregivers.

D. Kashy, N. Hanna, V. Champion, 2016, Journal of pain and symptom management.

Maintenance Oral Etoposide After High-Dose Chemotherapy (HDCT) for Patients With Relapsed Metastatic Germ-Cell Tumors (mGCT).

N. Hanna, L. Einhorn, R. Abonour, 2023, Clinical genitourinary cancer.

Survival outcomes and toxicity in patients 40 years old or older with relapsed metastatic germ cell tumors treated with high‐dose chemotherapy and peripheral blood stem cell transplantation

N. Hanna, L. Einhorn, M. A. Abu Zaid, 2021, Cancer.

Risk Factors for Acute Kidney Injury During High-dose Chemotherapy and Outcomes for Patients With Relapsed Germ Cell Tumors.

N. Hanna, L. Einhorn, C. Albany, 2020, Clinical Genitourinary Cancer.

Late relapse of germ cell tumors: Detection and treatment outcomes.

N. Hanna, L. Einhorn, T. Masterson, 2021 .

Phase I/II study of MKC-1 and pemetrexed (PEM) as second-line therapy in patients (pts) with advanced non-small cell lung cancer (NSCLC).

N. Hanna, G. Clamon, H. West, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Maintenance daily oral etoposide versus no further therapy following induction chemotherapy with etoposide plus ifosfamide plus cisplatin in extensive small-cell lung cancer: a Hoosier Oncology Group randomized study.

N. Hanna, L. Einhorn, A. Sandler, 2002, Annals of oncology : official journal of the European Society for Medical Oncology.

Long-Term Toxicity of Radiation Therapy

N. Hanna, R. Timmerman, L. Einhorn, 2003 .

LAL deficiency induced myeloid-derived suppressor cells as targets and biomarkers for lung cancer

N. Hanna, S. Jalal, H. Du, 2023, Journal for ImmunoTherapy of Cancer.

Phase III Randomized Trial of Cisplatin Plus Placebo Compared With Cisplatin Plus Cetuximab in Metastatic/Recurrent Head and Neck Cancer: An Eastern Cooperative Oncology Group Study

N. Hanna, 2007 .

Randomized, Double-Blinded, Multicenter, Phase II Study of Pemetrexed, Carboplatin, and Bevacizumab with Enzastaurin or Placebo in Chemonaïve Patients with Stage IIIB/IV Non-small Cell Lung Cancer: Hoosier Oncology Group LUN06-116

N. Hanna, J. Latz, J. Patel, 2010, Journal of Thoracic Oncology.

P1.18-05 ChemoXRT W/ Consolidation Pembrolizumab in Unresectable Stage III NSCLC: Long-Term Survival Update and Analysis of Post-Progression Therapy

N. Hanna, S. Jalal, R. Zon, 2019, Journal of Thoracic Oncology.

Time since start of first-line therapy as a predictive clinical marker for nintedanib in patients with previously treated non-small cell lung cancer

N. Hanna, R. Kaiser, S. Novello, 2017, ESMO Open.

Individual Patient Data Meta-Analysis of Docetaxel Administered Once Every 3 Weeks Compared With Once Every Week Second-Line Treatment of Advanced Non–Small-Cell Lung Cancer

N. Hanna, 2008 .

Coping with physical and psychological symptoms: a qualitative study of advanced lung cancer patients and their family caregivers

N. Hanna, V. Champion, S. Jalal, 2015, Supportive Care in Cancer.

Acceptance and Commitment Therapy for Symptom Interference in Advanced Lung Cancer and Caregiver Distress: A Pilot Randomized Trial.

N. Hanna, V. Champion, L. Einhorn, 2019, Journal of pain and symptom management.

Gefitinib in patients with chemo-sensitive and chemo-refractory relapsed small cell cancers: a Hoosier Oncology Group phase II trial.

N. Hanna, R. Govindan, Menggang Yu, 2006, Lung cancer.

A phase I trial of plinabulin in combination with nivolumab and ipilimumab in patients with relapsed small cell lung cancer (SCLC): Big Ten Cancer Research Consortium (BTCRC-LUN17-127) study.

N. Hanna, S. Jalal, S. Jabbour, 2021 .

Acceptability and Feasibility of a Meaning-Based Intervention for Patients With Advanced Cancer and Their Spouses A Pilot Study

N. Hanna, S. Bigatti, S. Johns, 2016 .

Acceptability and Feasibility of a Meaning-Based Intervention for Advanced Cancer Patients and Their Spouses : A Pilot Study

N. Hanna, S. Bigatti, C. Wagner, 2017 .

G. Pond, N. Hanna, L. Einhorn, 2017, Clinical genitourinary cancer.

Phase II trial of pembrolizumab in patients (pts) with incurable platinum refractory germ cell tumors (GCT).

N. Hanna, L. Einhorn, C. Albany, 2017 .

High‐dose chemotherapy plus peripheral blood stem cell transplantation for patients with relapsed germ cell tumors and active brain metastases

N. Hanna, L. Einhorn, R. Abonour, 2019, Cancer.

A phase II trial of olanzapine and palonosetron for the prevention of chemotherapy induced nausea and vomiting (CINV).

N. Hanna, L. Einhorn, S. Passik, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Interim safety analysis of consolidation nivolumab and ipilimumab versus nivolumab alone following concurrent chemoradiation for unresectable stage IIIA/IIIB NSCLC: Big Ten Cancer Research Consortium LUN 16-081.

N. Hanna, A. Ganti, S. Jabbour, 2019, Journal of Clinical Oncology.

OA01.07 Updated Results of a Phase II Trial of Concurrent Chemoradiation with Consolidation Pembrolizumab in Patients with Unresectable Stage III NSCLC

N. Hanna, S. Jalal, R. Zon, 2018, Journal of Thoracic Oncology.

Lung Cancer Screening Knowledge in Four Internal Medicine Programs

N. Hanna, O. Abdul-Kafi, Nishraj Basnet, 2022, Cancer control : journal of the Moffitt Cancer Center.

Lung Cancer Screening Knowledge Among Internal Medicine Residents in a University Program

N. Hanna, Samuel Urrutia Argueta, 2020, Journal of Cancer Education.

Three‐arm, randomized, phase 2 study of carboplatin and paclitaxel in combination with cetuximab, cixutumumab, or both for advanced non–small cell lung cancer (NSCLC) patients who will not receive bevacizumab‐based therapy: An Eastern Cooperative Oncology Group (ECOG) study (E4508)

N. Hanna, F. Hirsch, S. Ramalingam, 2012, Cancer.

Phase III study of cisplatin (P) plus etoposide (E) with concurrent chest radiation (XRT) followed by docetaxel (D) vs. observation in patients (pts) with stage III non-small cell lung cancer (NSCLC): An interim toxicity analysis of consolidation therapy.

N. Hanna, R. Govindan, L. Einhorn, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Computer-Tailored Decision Support Tool for Lung Cancer Screening: Community-Based Pilot Randomized Controlled Trial

N. Hanna, P. Monahan, S. Rawl, 2020, Journal of medical Internet research.

Computer-Tailored Decision Support Tool for Lung Cancer Screening: Community-Based Pilot Randomized Controlled Trial (Preprint)

N. Hanna, P. Monahan, S. Rawl, 2019 .

A phase 2 trial of chemotherapy plus pembrolizumab in patients with advanced non–small cell lung cancer previously treated with a PD‐1 or PD‐L1 inhibitor: Big Ten Cancer Research Consortium BTCRC‐LUN15‐029

N. Hanna, S. Perkins, A. Traynor, 2022, Cancer.

Phase III Trial Comparing Supportive Care Alone With Supportive Care With Oral Topotecan in Patients With Relapsed Small-Cell Lung Cancer

N. Hanna, N. H. Hanna, 2008 .

O-5 Multiple regression analysis of prognostic variables for survival from the phase III study of pemetrexed versus docetaxel in non-small-cell lung cancer (NSCLC)

N. Hanna, P. Bunn, F. Shepherd, 2003 .

Phase III Study Comparing Cisplatin Plus Fluorouracil to Paclitaxel, Cisplatin, and Fluorouracil Induction Chemotherapy Followed by Chemoradiotherapy in Locally Advanced Head and Neck Cancer

N. Hanna, 2007 .

LBA40_PRTARGET: A RANDOMIZED, PHASE II TRIAL COMPARING VINTAFOLIDE VERSUS VINTAFOLIDE PLUS DOCETAXEL, VERSUS DOCETAXEL ALONE IN SECOND-LINE TREATMENT OF FOLATE-RECEPTOR-POSITIVE NON-SMALL CELL LUNG CANCER (NSCLC) PATIENTS

N. Hanna, R. Ramlau, E. Juhász, 2014 .

Safety and feasibility of consolidation pembrolizumab following concurrent chemoradiation for unresectable stage III non-small cell lung cancer: Hoosier Cancer Research Network LUN14-179.

Cynthia S. Johnson, N. Hanna, S. Jalal, 2017 .

Linifanib treatment in patients with non-small cell lung cancer (NSCLC): Phase II results.

N. Hanna, D. Gandara, R. Salgia, 2010 .

Phase I multicenter trial of BMS-690514: Safety, pharmacokinetic profile, biological effects, and early clinical evaluation in patients with advanced solid tumors and non-small cell lung cancer

N. Hanna, R. Herbst, F. Shepherd, 2008 .

Prophylactic Cranial Irradiation in Extensive Small-Cell Lung Cancer

N. Hanna, 2008 .

Decision Analysis for Prophylactic Cranial Irradiation for Patients With Small-Cell Lung Cancer

N. Hanna, 2008 .

Long-Term Toxicity of Chemotherapy

N. Hanna, R. Timmerman, L. Einhorn, 2003 .

Relations of perceived injustice to psycho‐spiritual outcomes in advanced lung and prostate cancer: Examining the role of acceptance and meaning making

N. Hanna, S. Jalal, E. Secinti, 2022, Psycho-oncology.

Primary Retroperitoneal Lymph Node Dissection for Stage II Seminoma: Is Surgery the New Path Forward?

N. Hanna, L. Einhorn, T. Masterson, 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Acceptability and Feasibility of a Meaning-Based Intervention for Patients With Advanced Cancer and Their Spouses

N. Hanna, S. Bigatti, S. Johns, 2016, The American journal of hospice & palliative care.

Phase II trial of concurrent chemoradiation with consolidation pembrolizumab in patients with unresectable stage III non-small cell lung cancer: Hoosier Cancer Research Network LUN 14-179.

N. Hanna, S. Jalal, R. Zon, 2018 .

Three-dimensional lymph node volume and craniocaudal lymph node length as an independent risk factor for recurrence or presence of micrometastatis in clinical stage I non-seminomatous germ cell tumors: A retrospective study.

M. Kohli, N. Hanna, L. Einhorn, 2015 .

Phase III Study of Docetaxel Compared With Vinorelbine in Elderly Patients With Advanced Non–Small-Cell Lung Cancer: Results of the West Japan Thoracic Oncology Group Trial (WJTOG 9904)

N. Hanna, 2007 .

Randomized Phase III Trial of Low-dose Isotretinoin for Prevention of Second Primary Tumors in Stage I and II Head and Neck Cancer Patients

N. Hanna, 2007 .

Prognostic Variables Associated With Improved Outcomes in Patients With Stage III NSCLC Treated With Chemoradiation Followed by Consolidation Pembrolizumab: A Subset Analysis of a Phase II Study From the Hoosier Cancer Research Network LUN 14-179.

N. Hanna, S. Althouse, G. Durm, 2019, Clinical lung cancer.

A retrospective analysis of patients with intermediate-risk germ cell tumor (IRGCT) treated at Indiana University from 2000 to 2010.

N. Hanna, S. Perkins, L. Einhorn, 2012 .

Antimetabolites in the management of non-small cell lung cancer

N. Hanna, L. Budde, 2005, Current treatment options in oncology.

Phase II study of fosaprepitant +5HT3 receptor antagonist + dexamethasone in patients with germ cell tumors undergoing 5-day cisplatin-based chemotherapy: A Hoosier Cancer Research Network Study.

N. Hanna, L. Einhorn, C. Fausel, 2015 .

Phase II Study of Etoposide and Cisplatin With Concurrent Twice-Daily Thoracic Radiotherapy Followed by Irinotecan and Cisplatin in Patients With Limited-Disease Small-Cell Lung Cancer: West Japan Thoracic Oncology Group 9902

N. Hanna, 2008 .

Phase III Study of Adjuvant Vaccination With Bec2/Bacille Calmette-Guerin in Responding Patients With Limited-Disease Small-Cell Lung Cancer (European Organisation for Research and Treatment of Cancer 08971-08971B; Silva Study)

N. Hanna, 2007 .

Optimal Duration of Maintenance Checkpoint Inhibitor Therapy in Patients With Advanced NSCLC.

N. Hanna, G. Durm, N. Shukla, 2021, JCO Oncology Practice.

Phase I/II Trial of Carboplatin, Nab-paclitaxel, and Pembrolizumab for Advanced Non-Small Cell Lung Cancer: Hoosier Cancer Research Network LUN13-175.

N. Hanna, S. Jalal, I. Helenowski, 2023, The Oncologist.

The differential efficacy of pemetrexed according to NSCLC histology: a review of two Phase III studies.

G. Scagliotti, N. Hanna, F. Shepherd, 2009, The oncologist.

Adding Gemcitabine to Paclitaxel/Carboplatin Combination Increases Survival in Advanced Non–Small-Cell Lung Cancer: Results of a Phase II-III StudyPaccagnella A, Oniga F, Bearz A, et al (Med Oncology Department, Venezia, Italy; Centro Riferimento Oncologico, Aviano, Italy; Azienda Ospedaliera, Padov

N. Hanna, 2007 .

The effects of hypogonadism on quality of life in survivors of germ cell tumors treated with surgery alone versus surgery plus platinum-based chemotherapy

N. Hanna, L. Einhorn, P. Monahan, 2019, Supportive Care in Cancer.

Survival of Patients with Stage I Lung Cancer Detected on CT Screening

O. Miettinen, C. Henschke, D. Yankelevitz, 2008 .

Women's Susceptibility to Tobacco Carcinogens and Survival After Diagnosis of Lung Cancer

N. Hanna, 2007 .

Surveillance after Complete Response to First-Line Chemotherapy in Patients with Metastatic Nonseminomatous Germ Cell Tumor

N. Hanna, L. Einhorn, T. Masterson, 2022, The Journal of urology.

Gefitinib plus celecoxib in chemotherapy-naïve patients with stage IIIB/IV non-small cell lung cancer (NSCLC): A phase II study from the Hoosier Oncology Group.

N. Hanna, L. Einhorn, D. Taber, 2006, Journal of Clinical Oncology.

Tobacco cessation and control a decade later: American society of clinical oncology policy statement update.

N. Hanna, J. Mulshine, Courtney A Tyne, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.